WO1998055150A8 - Txu-7-pap immunotoxin and use thereof - Google Patents
Txu-7-pap immunotoxin and use thereofInfo
- Publication number
- WO1998055150A8 WO1998055150A8 PCT/US1998/011287 US9811287W WO9855150A8 WO 1998055150 A8 WO1998055150 A8 WO 1998055150A8 US 9811287 W US9811287 W US 9811287W WO 9855150 A8 WO9855150 A8 WO 9855150A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- txu
- pap immunotoxin
- immunotoxin
- pap
- leukemias
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50274699A JP2002511753A (en) | 1997-06-03 | 1998-06-03 | TXU-7-PAP immunotoxin and use thereof |
EP98925178A EP0996467A1 (en) | 1997-06-03 | 1998-06-03 | Txu-7-pap immunotoxin and use thereof |
CA002292426A CA2292426A1 (en) | 1997-06-03 | 1998-06-03 | Txu-7-pap immunotoxin and use thereof |
AU77188/98A AU7718898A (en) | 1997-06-03 | 1998-06-03 | Txu-7-pap immunotoxin and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4836497P | 1997-06-03 | 1997-06-03 | |
US60/048,364 | 1997-06-03 | ||
US09/014,028 US6372217B1 (en) | 1997-06-03 | 1998-01-27 | Methods for the treatment of CD7+ viral infection with TXU-7-PAP |
US09/014,028 | 1998-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998055150A1 WO1998055150A1 (en) | 1998-12-10 |
WO1998055150A8 true WO1998055150A8 (en) | 1999-12-29 |
Family
ID=26685557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011287 WO1998055150A1 (en) | 1997-06-03 | 1998-06-03 | Txu-7-pap immunotoxin and use thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US6372217B1 (en) |
EP (1) | EP0996467A1 (en) |
JP (1) | JP2002511753A (en) |
AU (1) | AU7718898A (en) |
CA (1) | CA2292426A1 (en) |
WO (1) | WO1998055150A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002361390A1 (en) * | 2001-12-14 | 2003-06-30 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
WO2003106479A2 (en) * | 2002-06-17 | 2003-12-24 | Parker Hughes Institute | Pokeweed antiviral protein polypeptides with antiviral activity |
US6936288B2 (en) * | 2003-06-10 | 2005-08-30 | Klearsen Corporation | Method and composition for the treatment of shingles and related afflictions |
US7311906B2 (en) * | 2004-04-30 | 2007-12-25 | Brigham Young University | Anti-viral activity of an anti-thymidine kinase monoclonal antibody |
US20100266495A1 (en) * | 2004-05-21 | 2010-10-21 | Brigham Young University | Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody |
US8551486B2 (en) * | 2004-05-21 | 2013-10-08 | Savoy Pharmaceuticals, Inc. | Monoclonal antibodies to human thymidine kinase to treat cancer |
US7837998B2 (en) * | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
PL3903829T3 (en) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
EP2506881B1 (en) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
WO2011082345A2 (en) * | 2009-12-30 | 2011-07-07 | Brigham Young University | Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
PT2691530T (en) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Cmv glycoproteins and recombinant vectors |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
BR112015013444B1 (en) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | USE OF AN IMMUNOCONJUGATE |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
EP3110445A4 (en) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
JP6746845B2 (en) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating TROP-2 positive cancer cells |
EP3313443B9 (en) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
GB201717966D0 (en) | 2017-10-31 | 2017-12-13 | Xenikos Bv | Immunotoxins, formulations thereof and their use in medicine |
WO2022239720A1 (en) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | Antibody having reduced binding affinity for antigen |
WO2022266535A1 (en) * | 2021-06-18 | 2022-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to regulate viral pathogenesis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
US4675386A (en) | 1979-11-27 | 1987-06-23 | Regents Of The University Of California | Monoclonal antibody methods and compositions specific for single antigens in antigen aggregates |
US4831117A (en) | 1986-01-03 | 1989-05-16 | Uckun Fatih M | Monoclonal antibody specific for human B-cells |
AU3582995A (en) | 1994-08-22 | 1996-03-14 | Regents Of The University Of Minnesota | Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer |
US5919457A (en) | 1996-01-11 | 1999-07-06 | Regents Of The University Of Minnesota | TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS |
-
1998
- 1998-01-27 US US09/014,028 patent/US6372217B1/en not_active Expired - Lifetime
- 1998-06-03 AU AU77188/98A patent/AU7718898A/en not_active Abandoned
- 1998-06-03 JP JP50274699A patent/JP2002511753A/en active Pending
- 1998-06-03 EP EP98925178A patent/EP0996467A1/en not_active Withdrawn
- 1998-06-03 CA CA002292426A patent/CA2292426A1/en not_active Abandoned
- 1998-06-03 WO PCT/US1998/011287 patent/WO1998055150A1/en not_active Application Discontinuation
-
1999
- 1999-12-03 US US09/453,641 patent/US6689362B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2002511753A (en) | 2002-04-16 |
US6689362B1 (en) | 2004-02-10 |
EP0996467A1 (en) | 2000-05-03 |
AU7718898A (en) | 1998-12-21 |
CA2292426A1 (en) | 1998-12-10 |
WO1998055150A1 (en) | 1998-12-10 |
US6372217B1 (en) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998055150A8 (en) | Txu-7-pap immunotoxin and use thereof | |
EP0528931A4 (en) | Humanized chimeric anti-icam-1 antibodies, methods of preparation and use | |
NO20005839D0 (en) | Preparations for the treatment of HIV and other viral infections | |
AU2001248331A1 (en) | Medicaments against viral diseases | |
ID26043A (en) | 1,2,5-TRIAZINA TRITIZED SUBSTITUTIONS FOR TREATMENT OF HIV INFECTIONS | |
MX9205401A (en) | TALK OF TRANSPORT OF SURGICAL INSTRUMENT. | |
DK0841949T3 (en) | Use of saccharide conjugates | |
ATE122237T1 (en) | HIV-1 NEUTRALIZING MONOCLONAL ANTIBODIES. | |
FR2700167B1 (en) | Pyrrolidine and thiazolidine derivatives, their preparation and the drugs containing them. | |
BR9711306A (en) | Cytotoxic amino a-Úcar and correlated indolopyrrolocarbazide a-Úcar derivatives | |
ES2191075T3 (en) | 8-ARILALQUIL- AND 8-ARILHETEROALQUIL-5,11-DIHIDRO-6H-DIPIRIDO- (3,2-B: 2 ', 3'-E) (1,4) DIAZEPINS AND THEIR USE IN THE PREVENTION OR TREATMENT OF INFECTIONS FOR HIV. | |
HUP9903420A3 (en) | Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections | |
WO1997025071A3 (en) | Immunoconjugate for the treatment of aids | |
AU2784792A (en) | Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv | |
AU7160691A (en) | Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes | |
EP0577243A3 (en) | Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection. | |
FI915780A (en) | MAERKTAE, MODIFIED OLIGONUCLEOTIDER. | |
ITVR940096A0 (en) | PROCEDURE AND EQUIPMENT FOR THE SPECIFIC IMMUNADORPTION OF HIV VIRUS, GP120 ANTIGEN AND CD4-GP120 COMPLEX. | |
EP0955366A4 (en) | Antigenic protein originating in malassezia | |
AU2880595A (en) | Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses | |
FI951655A0 (en) | Treatment of H.pylori infections | |
BR9914722A (en) | Anticonvulsant derivatives useful in the treatment of alcohol dependence, addiction and abuse | |
PL317876A1 (en) | Combined treatment of hiv infections | |
CA2088370A1 (en) | New use of monoclonal antibody | |
EP0655919A4 (en) | Treatment of human viral infections. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2292426 Country of ref document: CA Ref country code: CA Ref document number: 2292426 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998925178 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998925178 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998925178 Country of ref document: EP |